Akeso gains NMPA approval for cadonilimab to treat cervical cancer

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic cervical cancer.

Jun 7, 2025 - 06:00

Akeso gains NMPA approval for cadonilimab to treat cervical cancer

China’s NMPA has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to treat persistent, recurrent or metastatic cervical cancer.

Read the original article

Tags:

Previous Article

MHRA warns women using weight loss jabs must use effective contraception

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Navigator gains $100m in Series A funding for antibody therapeutics

Navigator gains $100m in Series A funding for antibody ...

Aug 29, 2024

FDA $7bn plans for 2024: disclose contract manufacturers, restart Cancer Moonshot

FDA $7bn plans for 2024: disclose contract manufacturer...

Mar 31, 2023

STAT+: Pharmalittle: We’re reading about a Lilly obesity-drug ad, a $35 cap on inhalers, and more

STAT+: Pharmalittle: We’re reading about a Lilly obesit...

Mar 8, 2024